drugset / Trial / NCT03629249
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over 52 weeks.
Timeline
- Start
- 2018-12-13
- Primary completion
- 2020-02-06
- Completion
- 2020-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fevipiprant | Small molecule | 150 mg | Oral |
| Subject | fevipiprant | Small molecule | 450 mg | Oral |